Paper3598607
Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH and 5 others. J Clin Oncol, 1987. Cited by 123 papers, by iCite.
Cite this record
ConductScience Library. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. Papers, record 3598607. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3598607
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia | Major topic |
| Lymphoma | Major topic |
| Neuroblastoma | Major topic |
| Podophyllotoxin | Major topic |
| Teniposide | Major topic |
| Child | |
| Drug Administration Schedule | |
| Drug Evaluation | |
| Humans | |
| Infusions, Parenteral | |
| Kinetics |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 20180 | NCI NIH HHS | United States | P01CA020180 | PubMed and NIH | NIH RePORTER |
| CA 21765 | NCI NIH HHS | United States | P30CA021765 | PubMed and NIH | NIH RePORTER |
| R01 CA 36401 | NCI NIH HHS | United States | R01CA036401 | PubMed and NIH | NIH RePORTER |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 29628775 | Prognostic significance of leukopenia during the induction phase in adult B cell acute lymphoblastic leukemia. | Cancer Manag Res | 2018 | https://conductscience.org/library/papers/29628775 | PubMed |
| 23116553 | Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients. | Br J Clin Pharmacol | 2013 | https://conductscience.org/library/papers/23116553 | PubMed |
| 18611060 | Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. | Clin Pharmacokinet | 2008 | https://conductscience.org/library/papers/18611060 | PubMed |
| 16524321 | Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. | Drug Saf | 2006 | https://conductscience.org/library/papers/16524321 | PubMed |
| 11523723 | Measures of exposure versus measures of rate and extent of absorption. | Clin Pharmacokinet | 2001 | https://conductscience.org/library/papers/11523723 | PubMed |
| 11108434 | Pharmacokinetically guided administration of chemotherapeutic agents. | Clin Pharmacokinet | 2000 | https://conductscience.org/library/papers/11108434 | PubMed |
| 10803455 | Adaptive control methods for the dose individualisation of anticancer agents. | Clin Pharmacokinet | 2000 | https://conductscience.org/library/papers/10803455 | PubMed |
| 9878990 | Practical treatment guide for dose individualisation in cancer chemotherapy. | Drugs | 1998 | https://conductscience.org/library/papers/9878990 | PubMed |
| 9761935 | Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy. | Pathol Oncol Res | 1998 | https://conductscience.org/library/papers/9761935 | PubMed |
| 9113440 | Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. | Clin Pharmacokinet | 1997 | https://conductscience.org/library/papers/9113440 | PubMed |
| 8611379 | Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8611379 | PubMed |
| 8335040 | Pharmacokinetic and pharmacodynamic data and models in clinical trials. | Eur J Drug Metab Pharmacokinet | 1993 | https://conductscience.org/library/papers/8335040 | PubMed |
| 8324869 | Disposition of total and unbound etoposide following high-dose therapy. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8324869 | PubMed |
| 8229682 | Targeting the systemic exposure of teniposide in the population and the individual using a stochastic therapeutic objective. | J Pharmacokinet Biopharm | 1993 | https://conductscience.org/library/papers/8229682 | PubMed |
| 8070032 | Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070032 | PubMed |
| 8070021 | Teniposide: overview of its therapeutic potential in adult cancers. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070021 | PubMed |
| 3289632 | Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. | Blut | 1988 | https://conductscience.org/library/papers/3289632 | PubMed |
| 2731312 | Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2731312 | PubMed |
| 2661101 | Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. | Clin Pharmacokinet | 1989 | https://conductscience.org/library/papers/2661101 | PubMed |
| 2245178 | Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. | Br J Cancer | 1990 | https://conductscience.org/library/papers/2245178 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3598607
GET https://conductscience.org/api/papers/v1/3598607/cited_by?page=2